News

News

Press releases

December 14, 2017
Kyn Therapeutics Announces $49 Million Series A Capital Available to Develop Cancer Therapy Candidates with Novel Approaches to Major Immunometabolism Pathways

view all Tweets

Twitter

@KynTherapeutics
Check out our website and subscribe to our newsletter (at the bottom) to hear the latest as we grow.… http://bcPCRw0EBS

@KynTherapeutics
To achieve this, we will disrupt immunosuppressive pathways to empower a broader, durable immune response to tumors… http://tPXTbQzwS1

@KynTherapeutics
At Kyn, we envision a future where immunotherapies are the foundation of every #cancer patient's treatment. http://UFMERiDGKh

@KynTherapeutics
AHR is an immunosuppressive receptor we're exploring as a target in our preclinical activity - read more about it:… http://ChoiK5WXTY

Media contact

Tom Donovan
Ten Bridge Communications
857-559-3397
tom@tenbridgecommunications.com

Alerts

Sign up to get up-to-date news about Kyn Therapeutics.

Contact us

Find us

Kyn Therapeutics
1030 Massachusetts Avenue
Suite 400
Cambridge, MA 02138

Call us

1-857-273-8343

Email us

info@kyntherapeutics.com

Friend us

LinkedIn